

Synthesis and biological evaluation of sulfonylcyanoguanidines and sulfonamidonitroethylenes as bioisosteres of hypoglycemic sulfonylureas

B Masereel^{1*}, R Ouedraogo², JM Dogné¹, MH Antoine², P de Tullio¹,
B Pirotte¹, L Pochet¹, J Delarge¹, P Lebrun²

¹Department of Medicinal Chemistry, University of Liège, 3, rue Fusch, 4000 Liège;

²Department of Pharmacology, University of Brussels, 808, route de Lennik, 1070 Brussels, Belgium

(Received 20 August 1996; accepted 6 November 1996)

Summary — Sulfonylcyanoguanidines and sulfonamidonitroethylenes are bioisosteres of hypoglycemic sulfonylureas and were prepared and evaluated for their insulin release potency from rat pancreatic islets. At 25 μ M, both bioisosteres of glibenclamide, sulfonylcyanoguanidine **22** and sulfonamidonitroethylene **23**, were as potent as their parent on insulin secretion.

sulfonylcyanoguanidine / sulfonamidonitroethylene / insulin secretion / diabetes



Introduction

The cyanoguanidine and the 1,1-diamino-2-nitroethylene functions are regarded as bioisosteres of the urea function [1]. This concept led to the discovery of powerful gastric antisecretory agents, such as cimetidine [2], a cyanoguanidine derivative, and ranitidine [3], a 1,1-diamino-2-nitroethylene compound. Recently, the cyanoguanidine bioisosteres of phenytoin [4], an antiepileptic acylurea, and torasemide [5], a diuretic sulfonylurea, were prepared and described as being less active than their leader. In this work, we applied a similar strategy to hypoglycemic sulfonylureas in order to obtain the corresponding sulfonylcyanoguanidines and sulfonamidonitroethylenes. As previously described [5], the presence of the electron-withdrawing groups (NC \equiv N and CH=NO₂) should preserve the required acidity of the sulfonamide moiety. Their potency as hypoglycemic drugs was evaluated by measuring insulin release from rat pancreatic islets.

Chemistry

The bioisosteres of hypoglycemic sulfonylureas were synthesized by refluxing the sodium salt of the

required sulfonamide **3** or **4** [6, 7] (scheme 1) with an excess of *N'*-substituted *N*-cyano-*S*-methylcarbamimidothioate **2a** or with 1-substituted amino-1-methylthio-2-nitroethylene **2b** to prepare sulfonylcyanoguanidines and 1-substituted amino-1-sulfonamido-2-nitroethylenes **5–23** (tables I and II). The carbamimidothioate derivatives and the nitro-



Scheme 1. (i) RNH₂, ethanol; (ii) NaOH, DMF, dioxane, reflux.

*Correspondence and reprints. Email: Bernard.Masereel@ulg.ac.be.

Table I. Effect of the first chemical generation bioisosteres on insulin release from rat pancreatic islets.

Compound	R	X	Drug concentration ($\mu\text{mol/L}$)	Percentage insulin release (mean \pm SE) ^a
5	(CH ₃) ₂ CH	NCN	100	NA
6	CH ₃ (CH ₂) ₃	NCN	100	NA
			25	NA
7	Cyclohexyl	NCN	100	NA
8	Cycloheptyl	NCN	100	NA
9	(CH ₂) ₅ =N	NCN	100	NA
10	(CH ₂) ₆ =N	NCN	25	NA
11	1-Azabicyclo[3.2.1]octane	NCN	25	NA
12	Cyclohexyl	CHNO ₂	25	223.1 \pm 15.3 ^b
Tolbutamide	CH ₃ (CH ₂) ₃	O	100	429.5 \pm 43.7 ^b
			25	363.5 \pm 32.5 ^b
Tolazamide	(CH ₂) ₆ =N	O	25	341.4 \pm 55.3 ^b
Gliclazide	1-Azabicyclo[3.2.1]octane	O	25	412.1 \pm 35.0 ^b

^aPercentage of insulin release from islets incubated in the presence of 8.3 mM glucose. Control (no added drug) was considered as 100%. NA = not active. ^bDifferent from control ($P < 0.05$).

Table II. Effect of the second chemical generation bioisosteres on insulin release from rat pancreatic islets.

Compound	R'	R	X	Percentage insulin release (mean \pm SEM) ^a
13	—	Cyclohexyl	NCN	143.3 \pm 9.5 ^b
14	2-Cl	Cyclohexyl	NCN	325.3 \pm 27.4 ^b
15	4-Cl	Cyclohexyl	NCN	132.9 \pm 10.9 ^b
16	3-CH ₃ O	Cyclohexyl	NCN	262.2 \pm 23.7 ^b
17	4-CH ₃ O	Cyclohexyl	NCN	125.2 \pm 10.5 ^b
18	3-F	Cyclohexyl	NCN	303.8 \pm 22.0 ^b
19	3-CF ₃	Cyclohexyl	NCN	255.4 \pm 19.6 ^b
20	2-CH ₃ O, 5-Cl	(\pm)-4-CH ₃ cyclohexyl	NCN	273.9 \pm 14.3 ^b
21	2-CH ₃ O, 5-Cl	Cyclopentyl	NCN	452.5 \pm 29.5 ^b
22	2-CH ₃ O, 5-Cl	Cyclohexyl	NCN	552.8 \pm 49.2 ^b
23	2-CH ₃ O, 5-Cl	Cyclohexyl	CHNO ₂	492.2 \pm 48.0 ^b
Glibenclamide	2-CH ₃ O, 5-Cl	Cyclohexyl	O	485.6 \pm 22.1 ^b

^aPercentage of insulin release from islets incubated in the presence of 8.3 mM glucose and 25 μM of drug. Control (no added drug) was considered as 100%. ^bDifferent from control ($P < 0.05$).

ethylene intermediate were obtained by reaction of the appropriate primary amine with *N*-cyano-*S,S'*-dimethyldithioiminocarbonate **1a** [8] or with 1,1-bismethylthio-2-nitroethylene **1b** [9].

At pH 7.40, the lipophilicity of the sulfonylcyano-guanidines **6** (log $P = +0.17 \pm 0.01$) and **22** (log $P =$

$+1.36 \pm 0.02$) was lower than that of their sulfonyl-urea counterparts, tolbutamide (log $P = +0.41 \pm 0.02$) and glibenclamide (log $P = +1.65 \pm 0.04$), respectively. The lipophilicity of the nitroethylene compound **23** was also lower (log $P = +1.34 \pm 0.02$) than that of glibenclamide.

In contrast to the ^1H -NMR spectrum of glibenclamide ($\delta = 10.27$, br s, 1H; 6.25, 1H, br d), that of **22** showed that the two protons of the cyanoguanidine ($\delta = 4.7$, br s, 2H) were indistinguishable and located with the residual water in the $\text{DMSO}-d_6$ solvent. For their nitroethylene bioisostere **23**, the nitroethylene proton ($\delta = 5.60$, s, 1H) and the proton of the distal nitrogen ($\delta = 8.92$, br d, 1H) were separated. These data suggest tautomeric forms of the sulfonylcyanoguanidine moiety only.

Results and discussion

The compounds **5–12** (table I) are structurally related to the first chemical generation of hypoglycemic sulfonylureas ($\text{Y} = \text{CH}_3$). The sulfonylcyanoguanidines **6**, **10** and **11**, which are the bioisosteres of tolbutamide, tolazamide and gliclazide respectively, did not increase insulin secretion. At 25 μM , the nitroethylene **12** induced a twofold increase in insulin release (table I). It was more potent than its cyanoguanidine counterpart **7**, but was less active than tolbutamide ($P < 0.05$).

The compounds bearing a carboxamidoethyl side-chain **13–23** (table II) are chemically related to glibenclamide, one of the most powerful hypoglycemic sulfonylurea of the second chemical generation ($\text{Y} = \text{aryl}-\text{CONH}(\text{CH}_2)_2$). The presence of a cyclohexyl moiety reinforces the analogy with glibenclamide. A (\pm)-4- CH_3 -cyclohexyl residue was placed on the distal nitrogen of the sulfonylcyanoguanidine function (**20**) to design a side-chain similar to that of glimepiride, a recently described hypoglycemic sulfonylurea [10]. As shown in table II, the substitution of the benzene ring strongly affected the biological response. Indeed, the absence of any substituent on the benzene ring (**13**) and the presence of a polar group in position 4 (**15** and **17**) strongly reduced the biological response. In contrast, *ortho* (**14**) or *meta* substitution (**16**, **18**, **19**) enhanced the capacity of these drugs to stimulate insulin secretion. The sulfonylcyanoguanidine **22** and the sulfonamido-nitroethylene **23** were as active as glibenclamide ($P > 0.05$), their sulfonylurea counterpart (table II).

In conclusion, this work led to the preparation of sulfonylcyanoguanidines and to the synthesis of a new chemical function, the 1-amino-1-sulfonamido-2-nitroethylene group. At 25 μM , the bioisosteres of glibenclamide **22** (BM 208) and **23** (BM 225) were as potent as the leader glibenclamide at increasing insulin release from rat pancreatic islets. Further investigations are warranted to elucidate their mechanism of action and to confirm their usefulness in the treatment of type II diabetes.

Experimental protocols

Chemistry

Elemental analyses for C, H, N, S were performed on a Carlo Erba EA 1108 analyzer and were within $\pm 0.4\%$ of theoretical values. Melting points were determined in open capillary with a Büchi Tottoli apparatus and were uncorrected. ^1H -NMR spectra were recorded on a Bruker 80 MHz using tetramethylsilane as internal standard and chemical shifts were expressed in part per million (δ). IR spectra were determined with a Perkin Elmer 1750 as KBr pellets. All reactions were routinely checked by TLC on silica gel 60F 254.

General procedure for the synthesis of sulfonylcyanoguanidines **5–11** and **13–22**

The *N*-substituted amino-*N*-cyano-*S*-methylcarbamimidothioates **2a** were prepared according to the previously described procedure [5]. In order to prepare the sulfonylcyanoguanidine **22**, the *N*-cyano-*N*-cyclohexyl-*S*-methylcarbamimidothioate (0.80 g, 4.1 mmol) was added to the sodium salt of 4-(5-chloro-2-methoxybenzamidoethyl)benzene sulfonamide (1 g, 2.7 mmol) dissolved in 5 mL of *N,N*-dimethylformamide/dioxane (3:2) and refluxed for 5 h. After evaporation of solvents under reduced pressure, the residue was dissolved in water (50 mL) and 2.5 N NaOH (5 mL). The solution was extracted three times with diethyl ether (50 mL) and adjusted to pH 1 with dilute hydrochloric acid. The precipitate was collected by filtration, washed with water, dried and recrystallized in ethanol to afford 0.71 g of **22** (yield: 51%). Mp = 92–95 °C; IR (KBr) 2188 cm^{-1} ($\text{C}\equiv\text{N}$ st). ^1H -NMR ($\text{DMSO}-d_6$) δ 8.18 (t, 1H, CONH), 7.75 (d, 2H, aryl- SO_2), 7.58 (d, 1H, $\text{ClC}=\text{CH}$), 7.4 (dd, 3H, aryl), 7.05 (d, 1H, $\text{CH}_3\text{OC}=\text{CH}$), 4.70 (br s, 2H, SO_2NH and *NH*-cyclohexyl), 3.72 (s, 3H, OCH_3), 3.25–3.65 (m, 3H, NHCH_2 and NHCH), 2.95 (m, 2H, CH_2 -aryl), 1.80–0.95 (m, 10H, cyclohexyl). Anal $\text{C}_{24}\text{H}_{28}\text{N}_5\text{O}_4\text{S}$ (518.04).

1-Cyclohexylamino-1-methylthio-2-nitroethylene **2b**

An excess of cyclohexylamine (2.1 mL, 18 mmol) was added to 1,1-bismethylthio-2-nitroethylene [9] (2.0 g, 12 mmol) and refluxed for 24 h. After cooling, the formed precipitate was filtered off, washed with ethanol and dried to give **2b** (yield: 75%). Mp = 101–103 °C; IR (KBr) 1563 cm^{-1} (asym NO_2 st). ^1H -NMR (80 MHz, $\text{DMSO}-d_6$) δ 10.37 (br s, 1H, NH), 6.68 (s, 1H, CHNO_2), 3.60 (m, 1H, NHCH), 2.45 (s, 3H, SCH_3), 1.95–1.05 (m, 10H, cyclohexyl). Anal $\text{C}_9\text{H}_{16}\text{N}_2\text{O}_2\text{S}$ (216.30).

General procedure for the synthesis of 1-cyclohexylamino-1-sulfonamido-2-nitroethylenes **12** and **23**

The nitroethylene **23** was obtained from reaction of an excess of 1-cyclohexylamino-1-methylthio-2-nitroethylene (0.90 g, 4.2 mmol) and 4-(5-chloro-2-methoxybenzamidoethyl)benzene sulfonamide (1 g, 2.7 mmol), following the procedure described above for **22**. The reaction gave 0.71 g of **23** (yield: 48%). Mp = 83–85 °C; IR (KBr) 1567 cm^{-1} (asym NO_2 st). ^1H -NMR ($\text{DMSO}-d_6$) δ 8.92 (br d, 1H, *NH*-cyclohexyl), 8.13 (t, 1H, CONH), 7.70 (d, 2H, aryl- SO_2), 7.60 (d, 1H, $\text{ClC}=\text{CH}$), 7.4 (dd, 3H, aryl), 7.07 (d, 1H, $\text{CH}_3\text{OC}=\text{CH}$), 5.60 (s, 1H, CHNO_2), 3.72 (s, 3H, OCH_3), 3.20–3.50 (m, 3H, NHCH_2 and NHCH), 2.83 (m, 2H, CH_2 -aryl), 1.95–0.90 (m, 10H, cyclohexyl). Anal $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_6\text{S}$ (537.04).

Lipophilicity

The lipophilicity of **6**, **22**, **23**, tolbutamide and glibenclamide was expressed as the logarithm of the partition coefficient ($\log P$) in *n*-octanol/phosphate buffer pH 7.40 by using the shake-flask technique [11].

Insulin release from incubated pancreatic rat islets [12]

Pancreatic islets were isolated from fed female rats. Groups of ten islets, each derived from the same batch of islets, were preincubated for 30 min at 37 °C in 1 mL of a buffered bicarbonate solution (in mM: NaCl 115, KCl 5, CaCl₂ 2.56, MgCl₂ 1.0, NaHCO₃ 24) supplemented with 2.8 mM D-glucose, 0.5% (w/v) dialysed albumin (fraction V) and bubbled with a mixture of O₂/CO₂ (95:5). The islets were then incubated at 37 °C for a further 90 min in 1 mL of the same buffered medium containing 8.3 mM D-glucose and, in addition, the required compound. Insulin release was measured radio-immunologically using rat insulin as standard.

Acknowledgments

R Ouedraogo was supported by a grant from Burkina Faso and from the Université Libre de Bruxelles. The authors are indebted to J Sergooris, M Hermann and P Neven for their technical assistance.

References

- 1 Thornber CW (1979) *Chem Soc Rev* 8, 563–580
- 2 Durant GJ, Emmett JC, Ganellin CR (1977) *J Med Chem* 20, 901–906
- 3 Brogden RN (1979) *Drugs* 24, 267–303
- 4 Lambert DM, Masereel B, Gallez B, Geurts M, Scriba GKE (1996) *J Pharm Sci* 85, 1077–1081
- 5 Masereel B, Dupont L, Laeckmann D et al (1995) *Eur J Med Chem* 30, 343–351
- 6 Arndt F, Martius C (1932) *Justus Liebigs Ann Chem* 499, 228–287
- 7 Weber H, Aumüller W, Muth K et al (1969) *Drug Research/Arz Forschung* 19, 1326–1346
- 8 Hantzsch A, Wolvekamp M (1904) *Justus Liebigs Ann Chem* 331, 264–297
- 9 Gompper R, Schaefer H (1967) *Chem Ber* 100, 591–604
- 10 Geisen K (1988) *Drug Research/Arz Forschung* 38, 1120–1130
- 11 Cloux JL, Crommen J, Delarge J, Pirard ML, Thunus L (1988) *J Pharm Belg* 43, 141–151
- 12 Lebrun P, Antoine MH, Ouedraogo R et al (1996) *J Pharmacol Exp Ther* 277, 156–162